<DOC>
	<DOCNO>NCT02342886</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety tolerability combination moxifloxacin , PA-824 , pyrazinamide treatment vary dos treatment lengths 4 6 month subject drug-sensitive ( DS ) pulmonary TB compare standard HRZE treatment . This study also assess efficacy , safety tolerability combination moxifloxacin , PA-824 , pyrazinamide treatment 6 month treatment subject multi drug-resistant ( MDR ) pulmonary TB compare combination moxifloxacin , PA-824 , pyrazinamide treatment DS-TB subject .</brief_summary>
	<brief_title>Shortening Treatment Advancing Novel Drugs</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Signed write consent witness oral consent case illiteracy , prior undertaking trialrelated procedure . 2 . Male female , age 18 year . 3 . Body weight ( light clothing shoe ) ≥ 30 kg . 4 . Sputum positive tubercule bacillus ( least 1+ International Union Against Tuberculosis Lung Disease ( IUATLD ) World Health Organization ( WHO ) scale smear microscopy trial laboratory . 5 . Drug‐Sensitive TB treatment arm subject : sensitive rifampicin rapid sputum base test ( may sensitive resistant isoniazid ) AND either newly diagnose TB patient history untreated least 3 year cure previous episode TB . If enter trial due sensitive rifampicin rapid sputum base test , however receipt rifampicin resistance test use indirect susceptibility test liquid culture show rifampicin resistant , : Excluded late exclusion ; Possibly replace determine sponsor . 6 . MDR‐TB treatment arm subject resistant rifampicin rapid sputum base test ( may sensitive resistant isoniazid ) . 7 . A chest xray opinion investigator compatible pulmonary TB . 8 . Be non‐childbearing potential use effective method birth control , define : Non‐childbearing potential : Subject ‐ heterosexually active practice sexual abstinence ; Female subject male subject female sexual partner ‐ bilateral oophorectomy , bilateral tubal ligation and/or hysterectomy postmenopausal history menses least 12 consecutive month ; Male subject female subject male sexual partner ‐ vasectomise bilateral orchidectomy minimally three month prior screen ; Effective birth control method : Double barrier method include male condom , diaphragm , cervical cap , female condom ; Female subject : Barrier method combine hormone‐based contraceptive intra‐uterine device female patient . Male subject ' female sexual partner : Double barrier method hormone‐based contraceptive intra‐uterine device female partner . willing continue practise birth control method plan conceive throughout treatment 12 week ( male subject ) 1 week ( female subject ) last dose trial medication discontinuation trial medication case premature discontinuation . ( Note : Hormone‐based contraception alone may reliable take IMP ; therefore , 1 . Any non TB related condition ( include myasthenia gravis ) participation trial , judge investigator , could compromise wellbeing subject prevent , limit confound protocol specify assessment . 2 . Being treat Malaria . 3 . Is critically ill , judgment investigator , diagnosis likely result death trial followup period . 4 . TB meningitis form extrapulmonary tuberculosis high risk poor outcome , likely require long course therapy ( TB bone joint ) , judge investigator . 5 . History allergy hypersensitivity trial IMP related substance , include know allergy fluoroquinolone antibiotic , history tendinopathy associate quinolones suspect hypersensitivity rifampicin antibiotic . 6 . For HIV infected subject follow : CD4+ count &lt; 100 cells/µL ; Karnofsky score &lt; 60 % ; Received intravenous antifungal medication within last 90 day ; WHO Clinical Stage 4 HIV disease . 7 . Resistant fluoroquinolones ( rapid , sputum base molecular screening test ) . If enter trial due sensitive fluoroquinolones rapid sputum base test , however receipt fluoroquinolones resistance test use indirect susceptibility test liquid culture show fluoroquinolones resistant , : Excluded late exclusion ; Possibly replace determine sponsor . 8 . Resistant pyrazinamide ( rapid , sputum base molecular screening test ) . DrugSensitive TB treatment arm subject may enter prior receipt rapid , sputum base molecular pyrazinamide resistance screen test result . On receipt result , resistant , : Excluded late exclusion ; Possibly replace determine sponsor . MDRTB treatment arm subject may enter prior receipt rapid , sputum base molecular pyrazinamide resistance screen test result show sensitive pyrazinamide . 9 . Having participated clinical trial investigational agent within 8 week prior trial start currently enrol investigational trial . 10 . Subjects follow screening ( per measurement read do Central Electrocardiogram ( ECG ) applicable ) : Cardiac arrhythmia require medication ; Prolongation QT/QTc interval QTcF ( Fridericia correction ) &gt; 450 m ; History additional risk factor Torsade de Pointes , ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) ; Any clinically significant ECG abnormality , opinion investigator . 11 . Unstable Diabetes Mellitus require hospitalization hyper hypoglycaemia within past year prior start screening . Specific Treatments 12 . Previous treatment PA824 part clinical trial . 13 . For DSTB treatment arm : Previous treatment tuberculosis within 3 year prior Day ( 9 1 ) ( Screening ) . Subjects previously receive isoniazid prophylactically may include trial long treatment is/was discontinue least 7 day prior randomization trial . For MDRTB Subjects : Previous treatment MDRTB , although may MDR TB treatment regimen longer 7 day start screen . Previous treatment TB include , limited , gatifloxacin , amikacin , cycloserine , rifabutin , kanamycin , paraaminosalicylic acid , rifapentine , thioacetazone , capreomycin , quinolones , thioamides , metronidazole . 14 . Any disease condition use standard TB drug component contraindicate , include limited allergy TB drug , component IMP . 15 . Use drug within 30 day prior randomisation know prolong QTc interval ( include , limited , amiodarone , amitriptyline , bepridil , chloroquine , chlorpromazine , cisapride , clarithromycin , disopyramide dofetilide , domperidone , droperidol , erythromycin , halofantrine , haloperidol , ibutilide , levomethadyl , mesoridazine , methadone , pentamidine , pimozide , procainamide , quinacrine , quinidine , sotalol , sparfloxacin , thioridazine ) . 16 . Use systemic glucocorticoid within one year start screening ( inhaled intranasal glucocorticoid allow ) . 17 . Subjects recently start expect need start antiretroviral therapy ( ART ) within 1 month randomization . Subjects may include ARTs great 30 day prior start screen , expect start ART great 30 day randomization . Laboratory Abnormalities 18 . Subjects follow toxicity screen define enhanced Division Microbiology Infectious Disease ( DMID ) adult toxicity table ( November 2007 ) , applicable : creatinine grade 2 great ( &gt; 1.5 time upper limit normal [ ULN ] ) ; creatinine clearance ( CrCl ) level le 30 mLs/min accord CockcroftGault Formula ; haemoglobin grade 4 ( &lt; 6.5 g/dL ) ; platelet grade 3 great ( 50x109 cells/L/ 50 000/mm3 ) ; serum potassium less low limit normal laboratory . This may repeat ; aspartate aminotransferase ( AST ) grade 3 great ( ≥3.0 x ULN ) ; alanine aminotransferase ( ALT ) grade 3 great ( ≥3.0 x ULN ) ; alkaline phosphatase ( ALP ) : grade 4 ( &gt; 8.0 x ULN ) exclude ; grade 3 ( ≥3.0 8.0 x ULN ) must discuss approve sponsor Medical Monitor ; total bilirubin : 2.0 x ULN , liver function normal range 1.50 x ULN accompany increase liver function test subject total bilirubin &gt; 1.25 x ULN accompany increase liver function test must discuss sponsor medical monitor enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Multi Drug-Resistant Tuberculosis</keyword>
	<keyword>Drug-sensitive Tuberculosis</keyword>
	<keyword>PA-824</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Pyrazinamide</keyword>
	<keyword>Rifampicin</keyword>
	<keyword>Isoniazid</keyword>
	<keyword>Ethambutol</keyword>
	<keyword>HRZE</keyword>
	<keyword>HR</keyword>
	<keyword>Pretomanid</keyword>
	<keyword>NC-006</keyword>
	<keyword>STAND</keyword>
</DOC>